Day: November 13, 2024

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and intraocular inflammation (IOI) profile numerically similar to approved anti-VEGF agents  4D-150 4FRONT Phase 3 program in wet AMD designed to maximize probability of success, continues to be on track with 4FRONT-1 trial initiation expected in Q1 2025 Continuing KOL engagement to expand awareness of the potential differentiated product profile of 4D-150 Company product portfolio strategy and cash utilization updates, together with SPECTRA clinical trial program and interim data updates in diabetic macular edema (DME), expected in early January 2025 $551 million in cash, cash equivalents and marketable securities as of September...

– Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients – – Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer – – Initial Data From At Least One Additional Arm of the Phase 2a Portion of the IMM-1-104 Phase 1/2a Trial Expected by Year End – – Cash Runway into Fourth Quarter 2025 – CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the third quarter ended September 30,...

Revenue Growth: Achieved second-quarter FY25 revenue of $11.9 million, a 33% increase from the first quarter’s revenue of $8.9 million. Improved Path to Profitability: Reported a net loss of $21.8 million, primarily impacted by non-cash, non-recurring, and extraordinary items, resulting in an Adjusted EBITDA¹ loss of $2.1 million, an improvement from the previous quarter’s Adjusted EBITDA loss of $2.8 million, reflecting a 25% sequential reduction powered by adoption of AI in reducing operating costs internally. Client Expansion: Added 5 new enterprise clients and over 150 agents and fleets, expanding our services to 108 enterprise clients across insurance and automotive sectors, and 3,550 agents and fleet customers globally. Balance Sheet Restructuring: Continued balance sheet reduction, negotiating a $3.6 million decrease in accounts...

AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025Poster presentation at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting highlighted AMPLIFY-7P Phase 1a translational data, demonstrating durable T cell response and antigen spreading in patients with KRAS mutant tumors Elicio to provide updated relapse-free survival (“RFS”) and overall survival (“OS”) data from AMPLIFY-201 study in an oral presentation at the 2024 European Society for Medical Oncology (“ESMO”) Immuno-Oncology Congress Strengthened cash position, expected to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics”...

SEATTLE, Nov. 13, 2024 (GLOBE NEWSWIRE) — Jones Soda Co. (CSE: JSDA, OTCQB: JSDA) (“Jones” or the “Company”), a beverage innovation company focused on developing, marketing and distributing cutting edge consumer drink and wellness products as well as leading brands in the cannabis infused beverage category space, announced its financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Summary vs. Year-Ago QuarterRevenue was $4.2 million compared to $4.5 million. The third quarter of 2024 included approximately $800,000 in revenue from the Company’s Mary Jones business compared to approximately $220,000 in the third quarter of 2023. Gross margin was 21.2% compared to 32.9% in the prior year quarter. Net loss was $2.6 million, or $(0.02) per share, compared to a net loss of $0.9 million, or...

TORTOLA, British Virgin Islands, Nov. 13, 2024 (GLOBE NEWSWIRE) — Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announces that it has filed its condensed consolidated interim financial statements and management’s discussion and analysis for the three and nine month periods ended September 30, 2024 (“Q3 2024“) with the Canadian securities regulatory authorities. All amounts are in United States dollars (“$”) unless otherwise stated. HighlightsRevenue decreased for Q3 2024 by 9% and by 13% for the nine months ended September 30, 2024 compared to the same prior year periods. Certain volumes were supplied as Protected Gas (as defined below) prior to July 31, 2024. After the termination of Protected Gas after July 31, 2024, those volumes...